Top

Published in:

01-08-2009 | Original Article

Breast cancer cells expressing stem cell markers CD44⁺ CD24^lo are eliminated by Numb-1 peptide-activated T cells

Authors: Takashi Mine, Satoko Matsueda, Yufeng Li, Hiroshi Tokumitsu, Hui Gao, Cristopher Danes, Kwong-Kwok Wong, Xinhui Wang, Soldano Ferrone, Constantin G. Ioannides

Published in: Cancer Immunology, Immunotherapy | Issue 8/2009

Abstract

Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-fluorouracil (5-FU) and (2) their elimination by Numb- and Notch-peptide activated CTL. The number of cells in all populations with the luminal CSC phenotype [epithelial specific antigen⁺ (ESA) CD44^hi CD24^lo, CD44^hi CD133⁺, and CD133⁺ CD24^lo] increased in drug-resistant MCF7 and SK-OV-3 cells. Similarly, the number of cells with expressed MIC-A/B increased 4 times in drug-resistant tumor cells compared with drug-sensitive cells. GEM^Res MCF7 cells had lower levels of the Notch-1-extracellular domain (NECD) and Notch trans-membrane intracellular domain (TMIC) than GEM^Sens MCF7. The levels of Numb, and Numb-L-[P]-Ser²⁶⁵ were similar in GEM^Res and GEM^Sens MCF7 cells. Only the levels of Numb-L (long)-Ser²⁹⁵ decreased slightly. This finding suggests that Notch-1 cleavage to TMIC is inhibited in GEM^Res MCF7 cells. PBMC activated by natural immunogenic peptides Notch-1 (2112–2120) and Numb-1 (87–95) eliminated NICD^positive, CD24^hi CD24^lo MCF7 cells. It is likely that the immunogenic Numb-1 peptide in MCF7 cells originated from Numb, [P]-lated by an unknown kinase, because staurosporine but not wortmannin and MAPK-inhibitors decreased peptide presentation. Numb and Notch are antagonistic proteins which degrade each other to stop and activate cell proliferation, respectively. Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments.

Available only for authorised users

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988PubMedCrossRef

Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, Rueger MA, Bae SK, Kittappa R, McKay RD (2006) Notch signaling regulates stem cell numbers in vitro and in vivo. Nature 442:823–826PubMedCrossRef

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615–5621PubMedCrossRef

Berdnik D, Torok T, Gonzalez-Gaitan M, Knoblich JA (2002) The endocytic protein a-adaptin is required for numb-mediated asymmetric cell division in Drosophila. Dev Cell 3:221–231PubMedCrossRef

Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S (1997) Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 90(2):281–291PubMedCrossRef

Bourguignon LY, Gilad E, Peyrollier K (2007) Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem 282:19426–19441PubMedCrossRef

Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham AD (2008) ã6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122(2):298–304PubMedCrossRef

Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O’Brian CA, Ioannides CG (2002) Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu proto-oncogene (369–377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol 169:3545–3554PubMed

Chapman G, Liu L, Sahlgren C, Dahlqvist C, Lendahl U (2006) High levels of Notch signaling down-regulate Numb and Numblike. J Cell Biol 175:535–540PubMedCrossRef

10.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951PubMedCrossRef

11.

Di Marcotullio L, Ferretti E, Greco A, De Smaele E, Po A, Sico MA, Alimandi M, Giannini G, Maroder M, Screpanti I, Gulino A (2006) Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat Cell Biol 8:1415–1423PubMedCrossRef

12.

Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth (2008) A resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111–1115PubMedCrossRef

13.

Efferson CL, Tsuda N, Kawano K, Nistal-Villan E, Sellappan S, Yu D, Murray JL, Garcia-Sastre A, Ioannides CG (2006) Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8 + cells to recognize noninfected tumor cells. J Virol 80:383–394PubMedCrossRef

14.

Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S (2007) Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol 2:166–175CrossRef

15.

Ishiyama S, Matsueda S, Jones LA, Efferson C, Celestino J, Schmandt R, Ioannides CG, Tsuda N, Chang DZ (2007) Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8⁺ cells in ovarian ascites. Int J Oncol 30:889–898PubMed

16.

Kawano K, Efferson CL, Peoples GE, Carter D, Tsuda N, Murray JL, Ioannides CG (2005) Sensitivity of undifferentiated, high-TCR density CD8 + cells to methylene groups appended to tumor antigen determines their differentiation or death. Cancer Res 65:2930–2937PubMedCrossRef

17.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679PubMedCrossRef

18.

Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 105(5):1680–1685PubMedCrossRef

19.

McGill MA, McGlade CJ (2003) Mammalian Numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 278:23196–23203PubMedCrossRef

20.

Morrison SJ, Kimble J (2006) Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441:1068–1074PubMedCrossRef

21.

Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan RA (2000) Ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol Cell 5(2):197–206PubMedCrossRef

22.

Nishimura T, Kaibuchi K (2007) Numb controls integrin endocytosis for directional cell migration with aPKC and PAR-3. Dev Cell 1:15–28CrossRef

23.

Orford KW, Scadden DT (2008) Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 9:115–128PubMedCrossRef

24.

Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH (2007) In vivo evidence for the role of CD44 in promoting breast cancer metastasis to the liver. Am J Pathol 171(6):2033–2039PubMedCrossRef

25.

Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24):1777–1785PubMedCrossRef

26.

Piekarz RL, Sackett DL, Bates SE (2007) Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J 13(1):30–39PubMedCrossRef

27.

Ratnam K, Low JA (2007) Current development of clinical inhibitors of poly (ADP-ribose)-polymerase in oncology. Clin Cancer Res 13:1383–1388PubMedCrossRef

28.

Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115PubMedCrossRef

29.

Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988–4002PubMedCrossRef

30.

Schroeter EH, Kisslinger JA, Kopan R (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393(6683):382–386PubMedCrossRef

31.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

32.

Smith CA, Lau KM, Rahmani Z, Dho SE, Brothers G, She YM, Berry DM, Bonneil E, Thibault P, Schweisguth F, Le Borgne R, McGlade CJ (2007) aPKC-mediated phosphorylation regulates asymmetric membrane localization of the cell fate determinant Numb. EMBO J 26:468–480PubMedCrossRef

33.

Surowiak P, Materna V, Kaplenko I, Spaczyński M, Dietel M, Kristiansen G, Lage H, Zabel M (2006) Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. Int J Gynecol Cancer 2:515–521CrossRef

34.

Tokumitsu H, Hatano N, Inuzuka H, Sueyoshi Y, Yokokura S, Ichimura T, Nozaki N, Kobayashi R (2005) Phosphorylation of Numb family proteins. Possible involvement of Ca2 +/calmodulin-dependent protein kinases. J Biol Chem 280:35108–35118PubMedCrossRef

35.

Tokumitsu H, Hatano N, Yokokura S, Sueyoshi Y, Nozaki N, Kobayashi R (2006) Phosphorylation of Numb regulates its interaction with the clathrin-associated adaptor AP-2. FEBS Lett 580(24):5797–5801PubMedCrossRef

36.

Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35:796–807PubMedCrossRef

37.

Tsuda N, Chang DZ, Mine T, Efferson C, García-Sastre A, Wang X, Ferrone S, Ioannides CG (2007) Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res 67:8378–8387PubMedCrossRef

38.

Wang H, Ouyang Y, Somers WG, Chia W, Lu B (2007) Polo inhibits progenitor self-renewal and regulates Numb asymmetry by phosphorylating Pon. Nature 449(7158):96–100PubMedCrossRef

39.

http://www.ncbi.nlm.nih.gov/geo/gds/profileGraph

Title: Breast cancer cells expressing stem cell markers CD44+ CD24lo are eliminated by Numb-1 peptide-activated T cells
Authors: Takashi Mine
Satoko Matsueda
Yufeng Li
Hiroshi Tokumitsu
Hui Gao
Cristopher Danes
Kwong-Kwok Wong
Xinhui Wang
Soldano Ferrone
Constantin G. Ioannides
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 8/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0623-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2009

Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients

TGF-alpha as a candidate tumor antigen for renal cell carcinomas

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis

Ablation of T cell immunity differentially influences tumor risk in inbred BD rat strains

Secretion of stress protein grp170 promotes immune-mediated inhibition of murine prostate tumor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer